In STRIVE, natalizumab treatment demonstrated effectiveness in clinical, magnetic resonance imaging (MRI), and patient-reported outcomes (PROs) in patients with early relapsing-remitting multiple sclerosis (RRMS). This post hoc analysis examined the effectiveness and safety of natalizumab in patients who self-identified as either Black/African American (AA) or Hispanic/Latino. Read more on the research conducted by Northwestern's Dr Roumen Balabanov investigating the impact of a #multiplesclerosis treatment in #AfricanAmerican and #Hispanic / #Latinx patients: https://lnkd.in/g2DhRKZP #Chicago #Chicagoland
